



SHAREABLE PDF

COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?

Kielan Darcy McAlinden¹, Mathew Suji Eapen ¹, Wenying Lu¹, Collin Chia^{1,2}, Greg Haug^{1,2} and Sukhwinder Singh Sohal¹

Affiliations: ¹Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia. ²Department of Respiratory Medicine, Launceston General Hospital, Launceston, Australia.

Correspondence: Sukhwinder Singh Sohal, Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Locked Bag – 1322, Newnham Drive, Launceston, Tasmania 7248, Australia. E-mail: sssohal@utas.edu.au

 @ERSpublications

Absolute cessation of any tobacco product in any form: implications for COVID-19 <https://bit.ly/3cyk9ra>

Cite this article as: McAlinden KD, Eapen MS, Lu W, *et al.* COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?. *Eur Respir J* 2020; 56: 2001645 [<https://doi.org/10.1183/13993003.01645-2020>].

This single-page version can be shared freely online.

To the Editor:

With great interest we read and commend the study done by Russo *et al.* [1], highlighting their findings that nicotine induces an increase in angiotensin-converting enzyme 2 (ACE-2) expression in human bronchial epithelial cells (HBEpC) and is mediated by $\alpha 7$ -subtype nicotinic receptors ($\alpha 7$ -nAChR). It raises the concern that all electronic nicotine-delivery systems may put users at greater risk of succumbing to coronavirus disease 2019 (COVID-19).